Effect of Carnitine on Uremic Cardiomyopathy

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients on chronic hemodialysis without obstructive coronary artery disease identified by coronary angiography were randomly divided into the two groups: carnitine group and control group. SPECT using FFA analogue, BMIPP, was performed before and one year after intravenous administration of L-carnitine (1000 mg on every dialysis session). Control group received the examination of BMIPP SPECT at the same time of the carnitine group. The effects of chronic intravenous administration of L-carnitine on myocardial fatty acid metabolism were investigated among this population.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Toujinkai Hospital

Criteria

Inclusion Criteria:

• Patients on chronic hemodialysis without significant obstructive coronary artery disease identified by angiography within one years of the study, and who had left ventricular dysfunction:

• reduced left ventricular systolic function (left ventricular ejection fraction <55%) and/or

• left ventricular hypertrophy evaluated by echocardiography)

Exclusion Criteria:

1. Moderate or worse valvular heart disease,

2. Past histories of acute or old myocardial infarction and/or coronary revascularization by percutaneous coronary intervention or coronary artery bypass grafting within one year of the study.